ProShare Advisors
ALGS icon

ProShare Advisors’s Aligos Therapeutics ALGS Stock Holding History

ProShare Advisors’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-407
Closed -$121K – 2201
2021
Q4 		$121K Buy
+407
New +$148K ﹤0.01% 2163

Other funds holding ALGS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

ProShare Advisors's ALGS Position: Q1 2022 in Review

ProShare Advisors sold out of Aligos Therapeutics (ALGS) in Q1 2022, closing a stake of 407 shares — an estimated $121K sold.

ProShare Advisors first reported a position in ALGS in Q4 2021 and held it in 1 quarter. The position peaked at $121K in Q4 2021. 76 funds tracked by Wall St. Rank hold ALGS as of Q1 2022.

  • ProShare Advisors reported no remaining Aligos Therapeutics position as of Q1 2022 after selling out during the quarter.
  • ProShare Advisors sold 407 Aligos Therapeutics shares in Q1 2022, an estimated $121K.
  • ProShare Advisors first reported a position in Aligos Therapeutics in Q4 2021 and held it in 1 quarter.
  • ProShare Advisors's Aligos Therapeutics position peaked at $121K in Q4 2021.
  • 76 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2022.

Based on ProShare Advisors's 13F filing for Q1 2022, filed 10 May 2022.